Pharma companies seeking approval for drugs along with companion diagnostics could see quicker FDA decisions as the agency moves toward a stricter preapproval path for the diagnostic portion of companion products.
Pharma companies seeking approval for drugs along with companion diagnostics could see quicker FDA decisions as the agency moves toward a stricter preapproval path for the diagnostic portion of companion products.